Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 10/20 | 0.50 |
| ▸ | MAPK13 | O15264 | 7/20 | 0.50 |
| ▸ | MAPK12 | P53778 | 7/20 | 0.50 |
| ▸ | MAPK11 | Q15759 | 7/20 | 0.50 |
| ▸ | EIF2AK2 | P19525 | 1/20 | 0.46 |
| ▸ | GSK3B | P49841 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5772757 | 0.95 | MAPK14 (0.49) | MAPK14MAPK13MAPK12MAPK11EIF2AK2 | |
| SCHEMBL5768257 | 0.93 | MAPK14 (0.48) | MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL5770227 | 0.92 | MAPK14 (0.47) | MAPK14MAPK13MAPK12MAPK11GSK3B | |
| SCHEMBL5772631 | 0.89 | MAPK14 (0.51) | MAPK14MAPK13MAPK12MAPK11EIF2AK2 | |
| SCHEMBL5772023 | 0.89 | GSK3B (0.47) | MAPK14MAPK13MAPK12MAPK11EIF2AK2 | |
| SCHEMBL5771552 | 0.88 | PIK3CG (0.58) | MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL5771427 | 0.88 | MAPK14 (0.56) | MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL5770752 | 0.87 | MAPK14 (0.52) | MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL5770263 | 0.86 | MAPK14 (0.59) | MAPK14MAPK13MAPK12MAPK11GSK3B | |
| SCHEMBL7215713 | 0.85 | MAPK14 (0.52) | MAPK14MAPK13MAPK12MAPK11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0988301-B1 | IMIDAZOLYL-CYCLIC ACETALS | AVENTIS PHARMA LTD (GB) | 2006-08-09 | — | — | EP | disclosed |
| US-6989395-B2 | Imidazolyl-cyclic acetals | AVENTIS PHARMA LIMITED (GB) | 2006-01-24 | — | — | US | disclosed |
| US-20040038991-A1 | Imidazolyl-cyclic acetals | AVENTIS PHARMA LIMITED (GB) | 2004-02-26 | — | — | US | disclosed |
| EP-0988301-A1 | IMIDAZOLYL-CYCLIC ACETALS | RHONE-POULENC RORER LIMITED (GB) | 2000-03-29 | — | — | EP | disclosed |
| WO-1998056788-A1 | IMIDAZOLYL-CYCLIC ACETALS | RHONE-POULENC RORER LIMITED (GB) | 1998-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040038991-A1 | Imidazolyl-cyclic acetals | CBR1, LBR, CBR3 | MAPK14 1915/4885MAPK13 1610/4885MAPK12 2766/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.